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Available online 21 March 2016AbstractObjectives: Reduced bone quality caused by vitamin C deficiency in older persons may lead to incidental fragility fractures during
bisphosphonate treatment, although bisphosphonate increases bone mineral density (BMD). This study aimed to evaluate the effects of min-
odronate and ascorbic acid (Aa) on BMD, bone quality, and bone strength in Aa-deficient osteogenic disorder Shionogi (ODS) rats.
Methods: Six-month-old ODS rats were divided into four groups (n ¼ 20 per group): (1) Aa supplementation (Aaþ); (2) Aa-deficient (Aa); (3)
Aa supplementation and minodronate administration (Aaþ þMino); and (4) Aa-deficient and minodronate administration (Aa þMino). BMD,
bone strength, bone histomorphometry, and bone quality determined using Fourier transform infrared spectroscopy imaging (FTIRI) were
evaluated after 4 and 8 weeks.
Results: BMD was significantly higher in the Aaþ þMino group than in the Aa group ( p < 0.05). Bone strength was significantly higher in the
Aaþ and Aaþ þ Mino groups than in the Aa group ( p < 0.05). Furthermore, bone strength was significantly higher in the Aaþ þ Mino group
than in the Aa þ Mino group ( p < 0.05). Minodronate treatment irrespective of Aa supplementation significantly decreased bone resorption
compared with the Aaþ and Aa groups ( p < 0.05). No significant differences in the parameters evaluated by FTIRI were observed between the
groups.
Conclusions: Aa supplementation improved bone strength in ODS rats. Combined treatment with minodronate and Aa, but not minodronate
alone, improved bone strength and increased BMD. Aa is required for bone health because it is essential for osteoblast differentiation.
© 2016 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fragility fractures in older people are related to the
impairment of their quality of life or reduced life expectancy
and comprise an important clinical issue in aging societies.
Prevention of fragility fractures is a very important clinical
topic. Regarding the prevention of fragility fractures, oral
administration of nitrogen-containing bisphosphonates* Corresponding author.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).reduced the relative risk of vertebral fractures from 36% to
49%, and that of nonvertebral fractures from 16% to 40% by
increasing bone mineral density (BMD) in postmenopausal
women [1e5]. Among nitrogen-containing bisphosphonates,
minodronate was at least 10 times more potent than alendro-
nate in inhibiting bone resorption by preventing the function of
osteoclasts in vitro [6,7] and by increasing BMD in ovariec-
tomized rats in vivo [8]. Minodronate clinically reduced the
vertebral fracture risk by 59% in postmenopausal women over
2 years [9]. However, although BMD is increased with min-
odronate therapy, minodronate cannot completely prevent new
vertebral or nonvertebral fractures, particularly in aged pa-
tients [9].Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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bisphosphonate treatment is the impairment of bone quality.
Bone quality is a broad term encompassing the factors
affecting the structural and material properties of bone. Ma-
terial properties are explained by the mineral/matrix ratio,
crystallite maturity and size, collagen cross-links, and
microdamage.
Ascorbic acid (Aa; vitamin C) has been gaining attention as
a candidate for determining the material properties. Previous
in vitro studies have shown that Aa is essential for osteoblast
differentiation in animals and humans [10,11]. Aa is an
indispensable coenzyme for the hydroxylation of lysine and
proline residues that are necessary for collagen triple-helix
formation, and the presence of collagen triple helices is
essential for the promotion of osteoblast differentiation
[12e15]. Aa also modulates the expression of transcription
factors such as osterix, which are critical for osteoblast dif-
ferentiation [16]. However, the in vivo effects of Aa on bone
quality, such as the mineral/matrix ratio or crystallite maturity
and size, remain unknown.
The blood level of Aa is lower in older people because of
decreased absorption from the intestine and reabsorption from
the kidney [17e20]. Thus, we speculated that a reason for
incidental fragility fractures during treatment with
bisphosphonates could be impairment of bone quality caused
by Aa deficiency in older people [17]. Therefore, we hy-
pothesized that treatment with minodronate and Aa may exert
additive effects on bone strength via increased BMD and
improved bone quality under Aa-deficient conditions in vivo.
To confirm this hypothesis, we used congenitally Aa-
deficient osteogenic disorder Shionogi (ODS) rats that are
unable to produce Aa. These rats cannot survive without Aa
supplementation, and their Aa levels are controlled by Aa
supplementation [21]. The purpose of this study was to eval-
uate the effects of minodronate and Aa on BMD, bone quality,
and bone strength in Aa-deficient ODS rats. Bone quality was
evaluated by Fourier transform infrared spectroscopy imaging
(FTIRI), which provides a way to explore bone quality at
multiple bone hierarchical levels [22].
2. Materials and methods2.1. AnimalsFour-month-old female ODS rats (mutant Wistar rats; Clea
Japan, Tokyo, Japan) were used [23]. Normal rats can syn-
thesize Aa; however, ODS rats have a hereditary defect in
ability to synthesize Aa because they lack L-gulono-g-lactone
oxidase [24,25]. When ODS rats are fed an Aa-free diet, their
polypeptide hydroxyproline levels, which are known to be
related to collagen synthesis [26], decrease below those in
normal rats after 1 week and are about one-third of the normal
level after 2 weeks [24,25]. When Aa is added to drinking
water, the scorbutic symptoms of these rats resolve in a few
days. The rats were housed in a controlled environment at
22 C with a 12-hour/12-hour light/dark cycle. They were
pair-fed and allowed ad libitum access to water as well asstandard Aa-free food (CE-2; Clea Japan) containing 1.14%
calcium, 1.06% phosphorus, and 250 IU vitamin D3 per 100 g
of food as previously described [27,28]. The rats received
2 mg/ml Aa (Iwaki Pharma, Tokyo, Japan) in their drinking
water for 4 months. At the age of 8 months, they received
0.5 mg/ml Aa in their drinking water [21] for 4 weeks to create
Aa-deficient conditions.2.2. Experimental designAfter a 4-week experimental period of feeding with Aa-
deficient (0.5 mg/ml) drinking water, the rats were divided
into the following four groups (n ¼ 20 per group): (1) Aa
supplementation (Aaþ) group, which received 2 mg/ml Aa-
supplemented water; (2) Aa-deficient (Aa) group, which
received 0.5 mg/ml Aa-deficient water; (3) Aa supplementa-
tion and minodronate (Aaþ þ Mino) group, which received
Aa-supplemented water and minodronate; (4) Aa-deficient and
minodronate (Aa  Mino) group, which received Aa-
deficient water and minodronate. In addition to these four
groups, Wistar rats of the same age (n ¼ 20) were included as
a control group. Minodronate (Astellas Pharma, Tokyo, Japan)
was dissolved in 0.1 M sodium acetate buffer (pH 7.2) con-
taining 0.1% bovine serum albumin. This was administered
subcutaneously once a week for 4 or 8 weeks (0.15 mg/kg
body weight) [8].
The animals were euthanized under anesthesia with an
intra-abdominal injection of ketamine (Sankyo, Tokyo, Japan)
and xylazine (Zenoaq, Fukushima, Japan), and the bilateral
femurs and tibias were harvested. Our animal experimental
protocols were approved by the Animal Committee of our
institution, and all animal experiments conformed to the
“Guidelines for Animal Experimentation” of our institution.2.3. BMD and sample preparationThe BMD of the right femur was measured in 2.5-mm
proximal regions of the femur by dual energy X-ray absorp-
tiometry (QDR-4500; Hologic Inc., Waltham, MA, USA).
Thereafter, the right femur and bilateral tibias were fixed in
neutral-buffered formalin until preparation for histological
examination and FTIRI. The left femurs were dissected of soft
tissue, wrapped in gauze moistened with saline, and frozen to
80 C until biomechanical testing.2.4. Bone histomorphometryThe left proximal halves of the tibias were decalcified in
neutral-buffered 10% ethylene diamine tetra-acetic acid for 3
weeks and embedded in paraffin. Next, 3-mm-thick mid-frontal
sections were prepared for hematoxylin and eosin (H & E)
staining for cancellous bone histomorphometry.
Bone histomorphometric analyses of H & E-stained sec-
tions of the left tibia were performed using a semiautomatic
graphic system (Histometry RT Camera; System Supply,
Nagano, Japan). Measurements were obtained in regions that
were 390 mm from the lowest point of the growth
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the primary spongiosa, and 390 mm from the endocortical
surface at a magnification of 200 [29]. The following his-
tomorphometric parameters were measured, as described
previously [30]: cancellous bone volume per tissue volume
(BV/TV); osteoid surface (OS/BS); and eroded surface (ES/
BS).2.5. Biomechanical testing procedureMechanical testing of the rat femoral shaft and femoral
neck was performed at room temperature using a materials
testing machine (MZ500S; Maruto, Tokyo, Japan).
For stabilization, the mid-diaphysis of the femur was placed
on two supports of the test apparatus that were 20 mm apart.
The load of a three-point bending test was applied in the
anteroposterior direction midway between the two supports. A
loadedisplacement curve was recorded at a crosshead speed of
5 mm/min. The maximum load (N), breaking energy (N$mm),
and breaking force (N) were calculated using software for the
measurement of bone strength (CTR win. Ver. 1.05; System
Supply). The maximum load was defined as the highest load,
and the breaking force was defined as the force at which
breakage occurred on the loadedeformation curve. The
breaking energy was defined as the area under the
loadedeformation curve up to the point at which breakage
occurred.
After the three-point bending test, the proximal part of the
femur was evaluated using a compression test of the femoral
neck. The diaphysis of the bone was embedded in a container
with methacrylate resin, and a vertical load was applied to the
top of the femoral head. A loadedisplacement curve was
recorded at a crosshead speed of 5 mm/min until the failure of
the femoral neck. The maximum load, breaking energy, and
breaking force on the loadedisplacement curve were calcu-
lated using the same software.2.6. Fourier transform infrared spectroscopy imagingTo evaluate bone quality, the right tibias were used for
FTIRI. Each right tibia was fixed in alcohol, embedded in
polymethylmethacrylate (PMMA), cut into 3-mm-thick sec-
tions, and mounted on barium fluoride infrared windows
(SpectraTech, Hopewell Junction, NY, USA). The unde-
calcified sections were examined using a PerkinElmerTable 1
Bone mineral density
Aaþ Aa Aaþ þ M
4 weeks n ¼ 10 n ¼ 10 n ¼ 10
BMD 0.253 ± 0.041 0.241 ± 0.032 0.272 ± 0
8 weeks n ¼ 10 n ¼ 10 n ¼ 10
BMD 0.257 ± 0.042 0.236 ± 0.049 0.281 ± 0
All values are expressed as mean ± standard deviation.
ANOVA, one-way analysis of variance; Aaþ, ascorbic acid supplementation gro
mentation and minodronate administration group; Aa þ Mino, ascorbic acid-defi
a p < 0.05 between Aa and Aaþ þ Mino groups by the Scheffe multiple compSpotlight 400 Infrared Imaging System (PerkinElmer In-
struments, Waltham, MA, USA) at a spectral resolution of
4 cm1. Mineral and matrix properties were assessed using
FTIRI in specific regions of the tibial cross-sections in
cortical and cancellous bone. For the bone area, five different
images were recorded. The mean and standard deviation (SD)
for five images in the bone area were calculated and
compared. The values were then averaged for each area. The
cross-sections were processed for FTIRI in a blinded fashion,
and the codes identifying the groups were not broken until
the time of the statistical analysis. Spectra were baseline-
corrected and the PMMA spectral contribution was sub-
tracted using OMNIC8, TQ Analyst (Thermo Fisher Scien-
tific, Kanagawa, Japan), as previously described [31]. The
mineral/matrix ratio, which measures bone mineral content
(correlated to ash weight), was calculated from the integrated
areas of phosphate (907e1,183 cm1) to amide I
(1,586e1,710 cm1). The collagen cross-linking network
maturity (XLR) was estimated as the peak intensity ratio of
amide I sub-bands at 1660 cm1. The carbonate/phosphate
ratio, which reflects the level of carbonate substitution in the
hydroxyapatite (HA) crystal, was calculated as the integrated
area of the n2 carbonate peak (840e892 cm1) to that of the
phosphate peak. The HA crystallinity, related to mineral
crystal size and perfection as determined by X-ray diffrac-
tion, was calculated as the phosphate sub-band 1,030/
1,020 cm1 peak intensity ratio.2.7. Statistical analysesAll values are expressed as mean ± SD. One-way analysis
of variance was used to test for statistical significance among
the groups. The significance levels of differences between two
groups among the Aaþ, Aa, Aaþ þMino, and Aa þMino
groups were assessed by the Scheffe multiple comparison
method at 4 and 8 weeks. Probability ( p) values of <0.05 were
considered statistically significant.
3. Results3.1. Minodronate increased bone mineral density in the
presence of ascorbic acid (Table 1)BMD was significantly increased at 4 and 8 weeks
( p ¼ 0.044 and 0.041, respectively) in the group thatino Aa þ Mino ANOVA Control
n ¼ 10 n ¼ 10
.051a 0.257 ± 0.044 <0.001 0.254 ± 0.052
n ¼ 10 n ¼ 10
.037a 0.261 ± 0.041 <0.001 0.256 ± 0.041
up; Aa, ascorbic acid-deficient group; Aaþ þ Mino, ascorbic acid supple-




Aaþ Aa Aaþ þ Mino Aa þ Mino ANOVA Control
4 Weeks n ¼ 10 n ¼ 10 n ¼ 10 n ¼ 10 n ¼ 10
Diaphysis three-point bending test
Maximum load (N) 118 ± 7a 95 ± 8 125 ± 9a,b 98 ± 6 <0.001 116 ± 5
Breaking energy (N$mm) 147 ± 5a 113 ± 6 161 ± 7a,b 129 ± 4 <0.001 150 ± 5
Breaking force (N) 69 ± 3a 45 ± 4 78 ± 6a,b 57 ± 4 <0.001 73 ± 5
Femoral neck compression test
Maximum load (N) 90 ± 6a 72 ± 5 95 ± 5a 78 ± 7 <0.001 95 ± 5
Breaking energy (N$mm) 84 ± 5a 67 ± 6 90 ± 4a,b 72 ± 7 <0.001 86 ± 5
Breaking force (N) 37 ± 5a 26 ± 4 42 ± 6a 29 ± 5 <0.001 40 ± 4
8 Weeks n ¼ 10 n ¼ 10 n ¼ 10 n ¼ 10 n ¼ 10
Diaphysis three-point bending test
Maximum load (N) 120 ± 6a 92 ± 7 128 ± 6a,b 101 ± 5 <0.001 117 ± 7
Breaking energy(N$mm) 150 ± 8a 111 ± 7 163 ± 6a,b 128 ± 7 <0.001 152 ± 5
Breaking force (N) 72 ± 3a 41 ± 4 79 ± 6a,b 58 ± 4 <0.001 71 ± 5
Femoral neck compression test
Maximum load (N) 93 ± 6a 69 ± 4 97 ± 5a 81 ± 7 <0.001 95 ± 4
Breaking energy (N$mm) 88 ± 4a 65 ± 5 94 ± 6a,b 71 ± 5 <0.001 85 ± 7
Breaking force (N) 39 ± 5a 25 ± 4 44 ± 6a 30 ± 4 <0.001 41 ± 6
All values are expressed as mean ± standard deviation.
ANOVA, one-way analysis of variance; Aaþ, ascorbic acid supplementation group; Aa, ascorbic acid-deficient group; Aaþ þ Mino, ascorbic acid supple-
mentation and minodronate administration group; Aa þ Mino, ascorbic acid-deficient and minodronate administration group.
a p < 0.05 vs. Aa group.
b p < 0.05 vs. Aa þ Mino group by the Scheffe multiple comparison method.
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tion (Aaþ þ Mino group) compared with that in Aa-deficient
rats (Aa group). Although the BMD in the Aa group ten-
ded to decrease, the decrease was not statistically significant
compared with the control and Aaþ groups. Minodronate
treatment without Aa supplementation (Aae þ Mino group)
failed to increase BMD at 4 and 8 weeks of treatment
compared with that in the Aa group.3.2. Ascorbic acid increased biomechanical strength
irrespective of minodronate administration (Table 2)The maximum load, breaking force, and breaking energy
determined by the mid-shaft three-point bending test were
significantly higher in the Aaþ group ( p ¼ 0.033, 0.033, and
0.032, respectively) and Aaþ þ Mino group ( p ¼ 0.030,Table 3
Bone histomorphometry
Aaþ Aa Aaþ þ
4 weeks n ¼ 10 n ¼ 10 n ¼ 10
BV/TV (%) 36.5 ± 3.2 31.6 ± 2.8 42.2 ±
OS/BS (%) 10.8 ± 1.1 8.9 ± 0.6 11.8 ±
ES/BS (%) 11.2 ± 0.4 11.5 ± 0.5 7.3 ± 0
8 weeks n ¼ 10 n ¼ 10 n ¼ 10
BV/TV (%) 37.1 ± 2.9 30.6 ± 2.5 44.3 ±
OS/BS (%) 10.3 ± 0.9 8.5 ± 0.5 12.1 ±
ES/BS (%) 11.5 ± 0.5 11.8 ± 0.4 7.1 ± 0
All values are expressed as mean ± standard deviation.
ANOVA, one-way analysis of variance; Aaþ, ascorbic acid supplementation gro
mentation and minodronate administration group; Aa þ Mino, ascorbic acid-defi
a p < 0.05 vs. Aa group.
b p < 0.05 vs. Aaþ group by the Scheffe multiple comparison method.0.029, and 0.031, respectively) than in the Aa group at 4
and 8 weeks. Furthermore, the maximum load, breaking
force, and breaking energy in the Aaþ þ Mino group were
significantly higher than in the Aa þ Mino group
( p ¼ 0.046, 0.048, and 0.045, respectively). Minodronate
administration without Aa supplementation (Aa þ Mino
group) failed to increase these parameters compared with the
Aa group at 4 and 8 weeks.
Similarly, the maximum load, breaking force, and breaking
energy of the femoral neck compression test were significantly
higher in the Aaþ group (p ¼ 0.033, 0.032, and 0.033,
respectively) and Aaþ þ Mino group (p ¼ 0.031, 0.027, and
0.029, respectively) than those in the Aa group at 4 and 8
weeks. The breaking energy, but not the maximum load or
breaking force, in the Aaþ þ Mino group was significantly
higher than that in the Aa þ Mino group (p ¼ 0.048).Mino Aa þ Mino ANOVA Control
n ¼ 10 n ¼ 10
3.1a 35.7 ± 3.7 <0.001 38.1 ± 2.7
0.8a 10.1 ± 0.5 <0.001 10.9 ± 0.8
.6a,b 7.1 ± 0.4a,b <0.001 8.8 ± 0.6
n ¼ 10 n ¼ 10
3.2a 35.8 ± 2.7 <0.001 38.3 ± 2.9
0.7a 10.3 ± 0.8 <0.001 10.5 ± 0.9
.6a,b 7.5 ± 0.5a,b <0.001 8.9 ± 0.4
up; Aa, ascorbic acid-deficient group; Aaþ þ Mino, ascorbic acid supple-
cient and minodronate administration group.
Fig. 1. Typical Fourier transform infrared images for the collagen cross-linking network maturity in cancellous and cortical bone. The yellow shaded part represents
normal maturity, the green dots represent lower maturity, and the red dots represent higher maturity of the collagen cross-linking network. The collagen cross-
linking network maturity tended to be higher in the Aaþ group than in the Aa group.
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(Aa þ Mino) treatment did not significantly increase these
parameters compared with those in the Aa group at 4 and 8
weeks.3.3. Bone histomorphometry (Table 3)BV/TV and OS/BS were significantly higher in the
AaþþMino group ( p¼ 0.043 and 0.037, respectively) than in
the Aa group at 4 and 8 weeks. The ES/BS was significantly
lower in the AaþþMino and AaþMino groups ( p¼ 0.044
and 0.041, respectively) than in the Aaþ and Aa groups.3.4. Ascorbic acid caused a non-significant increase in
the amount of mature collagen cross-linking in
cancellous bone, but not in cortical boneFig. 1 shows typical FTIRI for the collagen cross-linking
network maturity in cancellous bone. The yellow shaded
part shows normal maturity, the green dots reveal lower
maturity, and the red dots represent higher maturity of the
collagen cross-linking network. The Aaþ group showed many
red dots at the trabecular area (Fig. 1); whereas the Aa
group, Aaþ þ Mino group, and Aa þ Mino group showed
many green dots and few red dots (Fig. 1).
Table 4
Fourier transform infrared spectroscopy imaging of cancellous bone
Aaþ Aa Aaþ þ Mino Aa þ Mino ANOVA
4 weeks
Mineral/Matrix ratio 7.36 ± 1.19 7.01 ± 0.89 6.36 ± 0.80 8.02 ± 1.32 NS
Carbonate/phosphate ratio 0.00724 ± 0.00060 0.00903 ± 0.00078 0.00835 ± 0.00059 0.00895 ± 0.00051 NS
HA crystallinity 1.078 ± 0.028 1.058 ± 0.026 1.042 ± 0.023 1.049 ± 0.028 NS
Collagen cross-linking network maturity 4.702 ± 0.238* 4.079 ± 0.231 4.364 ± 0.161 4.110 ± 0.148 NS
8 weeks
Mineral/Matrix ratio 8.11 ± 1.06 5.90 ± 1.01 6.92 ± 0.89 8.13 ± 1.22 NS
Carbonate/phosphate ratio 0.00843 ± 0.00059 0.00875 ± 0.00063 0.00708 ± 0.00080 0.00894 ± 0.00073 NS
HA crystallinity 1.045 ± 0.032 1.066 ± 0.035 1.134 ± 0.031 1.041 ± 0.021 NS
Collagen cross-linking network maturity 4.792 ± 0.231 4.137 ± 0.161 4.480 ± 0.172 4.398 ± 0.101 NS
All values are expressed as mean ± standard deviation.
ANOVA, one-way analysis of variance; NS, not significant; Aaþ, ascorbic acid supplementation group; Aa, ascorbic acid-deficient group; Aaþ þ Mino, ascorbic
acid supplementation and minodronate administration group; Aa þ Mino, ascorbic acid-deficient and minodronate administration group.
There were no significant differences in the parameters among the study groups. *p ¼ 0.092 vs. Aa group by the Scheffe multiple comparison method.
Table 5
Fourier transform infrared spectroscopy imaging of cortical bone
Aaþ Aa Aaþ þ Mino Aa þ Mino ANOVA
4 weeks
Mineral/Matrix ratio 7.98 ± 0.88 7.37 ± 0.97 7.66 ± 0.84 7.44 ± 1.04 NS
Carbonate/phosphate ratio 0.00712 ± 0.00067 0.00967 ± 0.00075 0.00837 ± 0.00059 0.00924 ± 0.00051 NS
HA crystallinity 1.212 ± 0.024 1.071 ± 0.028 1.139 ± 0.027 1.127 ± 0.025 NS
Collagen cross-linking network maturity 3.803 ± 0.212 3.838 ± 0.186 3.729 ± 0.174 3.476 ± 0.158 NS
8 weeks
Mineral/Matrix ratio 7.70 ± 0.43 7.11 ± 0.62 7.71 ± 0.77 8.02 ± 0.78 NS
Carbonate/phosphate ratio 0.00789 ± 0.00022 0.00878 ± 0.00047 0.00735 ± 0.00051 0.00848 ± 0.00028 NS
HA crystallinity 1.179 ± 0.019 1.113 ± 0.038 1.145 ± 0.067 1.104 ± 0.026 NS
Collagen cross-linking network maturity 3.767 ± 0.091 3.656 ± 0.174 3.946 ± 0.362 3.821 ± 0.188 NS
All values are expressed as mean ± standard deviation.
ANOVA, one-way analysis of variance; NS, not significant; Aaþ, ascorbic acid supplementation group; Aa, ascorbic acid-deficient group; Aaþ þ Mino, ascorbic
acid supplementation and minodronate administration group; Aa þ Mino, ascorbic acid-deficient and minodronate administration group.
There were no significant differences among the study groups with regard to any of the parameters examined.
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Aa on bone quality (Fig. 1). However, there were no signifi-
cant differences in any of the FTIRI parameters examined for
cancellous bone among the study groups (Table 4). In
cancellous bone at 4 weeks, the collagen cross-linking
network maturity tended to be higher in the Aaþ group than
in the Aa group ( p ¼ 0.092).
There were no significant differences among the study
groups in any of the FTIRI parameters examined for cortical
bone (Table 5).
4. Discussion
In the present study, Aa deficiency caused lower bone
strength without decreasing BMD and causing lower bone
turnover as determined by bone histomorphometry in ODS
rats. A possible cause of the weakened bone strength in Aa-
deficient ODS rats is the impairment of bone quality, such
as decreases in the collagen cross-linked network in the
cancellous and cortical bone. However, no significant changes
in these parameters were detected using FTIRI in the present
study. To recover the decreased bone strength in ODS rats,
minodronate and Aa were administered. Minodronate could
not improve BMD or bone strength under Aa-deficientconditions, even with decreased bone resorption. Minodronate
and Aa supplementation, but not minodronate without Aa
supplementation, improved BMD and bone strength in ODS
rats.
ODS rats, as a model of Aa deficiency, show reduced bone
formation accompanied by deleterious effects in bone me-
chanical properties caused by decreased hydroxyproline in
collagen synthesis [26,32e34]. Hasegawa et al. [35] reported
that Aa deficiency causes several types of morphological de-
formities in bone mineralization and collagen, such as mis-
assembly of the triple helices of collagenous a-chains. These
observations indicate that Aa is essential for bone formation
and collagen synthesis related to bone quality.
We evaluated bone quality by FTIRI in the present study.
Aa supplementation did not increase the collagen cross-linking
network maturity of cancellous bone or HA crystallinity of
cortical bone in ODS rats. Collagen cross-linking network
maturity is related to the ratio of non-reducible to reducible
collagen cross-links, and HA crystallinity is a measure of
crystal size assessed by X-ray diffraction [36]. It has been
reported that the collagen cross-link ratio is partly responsible
for the changes in the material properties of osteoporotic bone,
contributing to clinically manifested fragility other than bone
turnover alone [37].
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been reported that Aa recovered bone volume, BMD, and bone
strength under osteoporotic conditions caused by oxidizing
stress in CuZn-SOD knockout mice [38]. In that study, Aa
showed antioxidant effects associated with the recovery of
bone strength in the fragile bone [38]. The findings of these
previous studies indicate that Aa improved bone quality and
increased bone strength. Although there were no significant
differences in the collagen cross-linking network maturity of
cancellous bone and HA crystallinity of cortical and cancel-
lous bone in ODS rats after 4 and 8 weeks of treatment in the
present study, the number of animals may not have been
sufficient to detect the effects of Aa supplementation on bone
quality evaluated by FTIRI.
Minodronate administration failed to increase BMD
without concurrent Aa supplementation and did not affect the
FTIRI results, although the bone resorption parameter ES/BS
was significantly decreased in ODS rats. In addition, min-
odronate did not cause a significant increase in bone strength
without Aa supplementation under Aa-deficient conditions.
With regard to the effect of minodronate on bone quality,
minodronate modifies bone mineral and matrix properties and
their heterogeneity; however, the bone homogenization
observed with minodronate use suggests that it also has
negative effects on bone quality [39]. In contrast, minodronate
prevented a change in the microarchitecture in ovariectomized
monkeys, indicating that minodronate did not have negative
effects on bone quality [40]. Although the effects of minodr-
onate on bone quality remain unclear, minodronate may not
exert a strong preventive effect on the incidence of fragility
fractures caused by worsened bone quality, such as that under
Aa-deficient conditions, which occur in some older patients
with insufficient Aa. Aa deficiency could explain why some
older patients have fragility fractures even while maintaining
BMD during treatment with bisphosphonates.
There have been no clinical studies on the combined ther-
apeutic effects of minodronate and Aa on the incidence of
fragility fractures in older patients. Combined therapy with
minodronate and Aa recovered the BMD and bone strength of
ODS rats in the present study. It has occasionally been re-
ported that fragility bone fractures increase with decreased
blood levels of Aa [41] and that callus strength after fracture is
increased by Aa supplementation [21]. The present findings
indicate that combined minodronate and Aa therapy may
decrease the incidence of fragility fractures in aged patients or
those with worsened bone quality.
There are several limitations to this study. First, the blood
level of Aa was not measured because blood was not extracted.
Therefore, it is not possible to accurately judge the extent to
which the blood level of Aa was decreased. Second, the
number of samples was not sufficient to detect significant
changes in parameters regarding bone quality evaluated by
FTIRI among the treatment groups. Third, the model used in
this study was not ovariectomized rats. Osteoporosis is com-
mon in older postmenopausal women, and thus ovariecto-
mized ODS rats may be more suitable to evaluate the effects of
Aa deficiency on BMD, bone quality, and bone strength.In summary, Aa deficiency caused lower bone turnover and
weakened bone strength without decreasing BMD in
congenitally Aa-deficient ODS rats. Aa supplementation
improved bone strength in ODS rats. Although minodronate
increased BMD, but not bone quality, it did not recover the
decreased bone strength in ODS rats. Combined treatment
with minodronate and Aa supplementation improved bone
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